DaVita Inc. announced its Q3 2026 financial results with consolidated revenues of $3.578 billion and diluted EPS of $3.40. The company reported a $62 million goodwill impairment charge related to its China business, impacting net income by $27 million. Operating cash flow was $519 million, and free cash flow was $276 million. DaVita repurchased 0.6 million shares for $111 million during the quarter and updated its 2026 guidance with adjusted operating income expected between $2.175 billion and $2.25 billion. The results reflect steady U.S. dialysis treatment growth and ongoing investments in integrated kidney care.
DaVita Inc. shares are trading at USD 189.81 on Pluang as of Oct 30, 2026 03:12 WIB, showing a strong 3.20% gain in the past day. This positive price movement coincides with the company's recent Q3 2026 results announcement, which highlighted steady growth in U.S. dialysis treatment and significant cash flow generation. Market participants on Pluang are fully buying DaVita stock, reflecting confidence in the health sector name despite the reported goodwill impairment charge.
Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop after the U.S. Department of Health and Human Services announced a new kidney care strategy. The federal plan aims to increase competition an...
Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop triggered by a new U.S. federal strategy targeting the dialysis market. The Department of Health and Human Services announced a plan to incre...
